Yahoo Finance5h
Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar
(ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program. The agreement enables ASTE, a pioneering healthcare distributor with over four ...
Seeking Alpha13h
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
In particular, the company's main value drivers address myotonic dystrophy type 1 [DM1], Duchenne muscular dystrophy [DMD], ...
Sarepta recent weakness brings buying opportunity, says JPMorgan
JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...
The Pharma Letter21h
Sarepta halts development of Duchenne drug as Elevidys soars
Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...